603259:SSEWuXi AppTec Co., Ltd. Class A Analysis
Data as of 2026-03-14 - not real-time
CN¥90.87
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
WuXi AppTec is trading at CNY 90.9, just above its 200‑day moving average (≈CNY 90.7) but comfortably below its 20‑day (≈CNY 96.6) and 50‑day (≈CNY 96.8) averages, indicating a neutral‑to‑slightly bearish short‑term stance. The RSI sits at 38, suggesting modest downside momentum, while the MACD shows a bearish divergence with a negative histogram, and volume has been trending lower, reinforcing a cautious outlook for the next few weeks. On the fundamentals side, the stock’s forward PE of 17.4x is well under the industry average of 26.2x, and its ROE of ~26% and 10% revenue growth highlight strong profitability and expansion potential. The company holds a robust cash pile of CNY 33.7 bn against CNY 9.1 bn of debt, yielding a comfortable net‑cash position, and it pays a 1.47% dividend with a modest 25% payout ratio, supporting dividend sustainability. However, the 30‑day volatility of 28% and a historical max drawdown of ~27% signal notable price swings, while the low beta (~0.3) tempers systematic market risk. No material news has emerged recently to shift this assessment, so investors should weigh the solid fundamentals against the technical weakness and elevated volatility when deciding on positioning.
Overall, the stock appears fairly valued when juxtaposing its low PE and strong cash generation against a DCF‑derived fair value of roughly CNY 56.7, which suggests limited upside from a pure valuation perspective. The blend of growth attributes (double‑digit revenue growth, high margins) and value cues (discounted multiples, solid dividend) makes it a candidate for a balanced, medium‑term hold, while short‑term traders may adopt a wait‑and‑see approach pending a clearer technical breakout.
Overall, the stock appears fairly valued when juxtaposing its low PE and strong cash generation against a DCF‑derived fair value of roughly CNY 56.7, which suggests limited upside from a pure valuation perspective. The blend of growth attributes (double‑digit revenue growth, high margins) and value cues (discounted multiples, solid dividend) makes it a candidate for a balanced, medium‑term hold, while short‑term traders may adopt a wait‑and‑see approach pending a clearer technical breakout.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Bearish MACD histogram and RSI below 40
- Price below 20‑day and 50‑day moving averages
- Decreasing trading volume
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- PE multiple well below industry average
- Strong ROE (~26%) and 10% revenue growth
- Healthy cash‑to‑debt balance and sustainable dividend
Long Term
> 3 yearsPositive
Model confidence: 6/10
Key Factors
- Long‑term tailwinds in CDMO and biotech services
- Robust cash reserves providing resilience to market cycles
- Diversified geographic footprint mitigating single‑region exposure
Key Metrics & Analysis
Financial Health
Revenue Growth10.40%
Profit Margin34.17%
P/E Ratio17.4
ROE25.91%
ROA11.28%
Debt/Equity12.72
P/B Ratio3.7
Op. Cash FlowCN¥15.4B
Free Cash FlowCN¥6.9B
Industry P/E26.2
Technical Analysis
TrendNeutral
RSI38.2
SupportCN¥89.10
ResistanceCN¥106.58
MA 20CN¥96.57
MA 50CN¥96.80
MA 200CN¥90.72
MACDBearish
VolumeDecreasing
Fear & Greed Index72.88
Valuation
Fair ValueCN¥56.72
GradeFair
TypeBlend
Dividend Yield1.47%
Risk Assessment
Beta0.29
Volatility28.09%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.